ECSP034891A - Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa - Google Patents

Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa

Info

Publication number
ECSP034891A
ECSP034891A EC2003004891A ECSP034891A ECSP034891A EC SP034891 A ECSP034891 A EC SP034891A EC 2003004891 A EC2003004891 A EC 2003004891A EC SP034891 A ECSP034891 A EC SP034891A EC SP034891 A ECSP034891 A EC SP034891A
Authority
EC
Ecuador
Prior art keywords
alkyl
derivatives
alkyloxy
independently
halogen
Prior art date
Application number
EC2003004891A
Other languages
English (en)
Inventor
Mingqiang Zhang
Simon James Anthony Grove
Mohammed Shahid
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of ECSP034891A publication Critical patent/ECSP034891A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un derivado de benzoxazepina que tiene la fórmula general I, en la cual X representa CO o SO2; R1, R2, R3 y R4 son independientemente seleccionados desde H, (C 1-4) alquilo, (C 1-4) alquiloxi, (C 1-4)alquiloxi(C 1-4)alquilo, CF3, halógeno, nitro, ciano, NR8R9, NR8COR10, y CONR8R9; R5, R6 y R7 son independientemente H o (C 1-4)alquilo; R8 y R9 son independientemente H o (C 1-4)alquilo; o R8 y R9 forman junto con el átomo de nitrógeno al cual están unidos al anillo heterocíclico saturado membrado 5- o 6-, conteniendo opcionalmente un hetero átomo adicional seleccionado desde O, S, o NR11; R10 es (C 1-4)alquilo; R11 es (C 1-4)alquilo; A representa el residuo de un anillo heterocíclico saturado membrado 4-7, opcionalmente conteniendo un átomo de oxígeno, el anillo siendo opcionalmente sustituido con sustituyentes 1-3 seleccionados desde (C 1-4)alquilo, (C 1-4)alquiloxi, hidroxi, halógeno u oxo; o una sal farmacéuticamente aceptable del mismo. LA invención también e refiere a composiciones farmacéuticas que comprenden dichos derivados, y el uso de estos derivados de benzoxazepina en el tratamiento de enfermedades neurológicas y desórdenes psiquiátricos los cuales responden al aumento de las respuestas sinápticas intermediadas por los receptores AMPA en el sistema nervioso central.
EC2003004891A 2001-06-11 2003-12-11 Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa ECSP034891A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01202215 2001-06-11

Publications (1)

Publication Number Publication Date
ECSP034891A true ECSP034891A (es) 2004-01-28

Family

ID=8180450

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004891A ECSP034891A (es) 2001-06-11 2003-12-11 Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa

Country Status (29)

Country Link
US (2) US7307073B2 (es)
EP (1) EP1399450B1 (es)
JP (1) JP4435561B2 (es)
KR (1) KR100863255B1 (es)
CN (1) CN1257908C (es)
AR (1) AR036092A1 (es)
AT (1) ATE389659T1 (es)
AU (1) AU2002314144B2 (es)
BR (1) BR0210222A (es)
CA (1) CA2450274C (es)
CO (1) CO5550447A2 (es)
CZ (1) CZ300052B6 (es)
DE (1) DE60225689T2 (es)
EC (1) ECSP034891A (es)
ES (1) ES2301651T3 (es)
HR (1) HRP20031007A2 (es)
HU (1) HUP0400154A3 (es)
IL (2) IL158905A0 (es)
IS (1) IS2526B (es)
MX (1) MXPA03011563A (es)
NO (1) NO328705B1 (es)
NZ (1) NZ529670A (es)
PE (1) PE20030097A1 (es)
PL (1) PL366721A1 (es)
RU (1) RU2279434C2 (es)
SK (1) SK287150B6 (es)
TW (1) TWI232863B (es)
WO (1) WO2002100865A1 (es)
ZA (1) ZA200309382B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345036B2 (en) 2001-06-14 2008-03-18 N.V. Organon (Pyrido/thieno)—[f]—oxazepine-5-one derivatives
WO2010054336A2 (en) * 2008-11-10 2010-05-14 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
DK2483278T3 (da) * 2009-09-28 2014-01-13 Hoffmann La Roche Benzoxazepin pi3k-inhibitorforbindelser og deres anvendelse i behandlingen af cancer
FR2964969B1 (fr) 2010-09-16 2012-08-24 Servier Lab Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3008167A4 (en) 2013-06-13 2017-06-07 VeroScience LLC Compositions and methods for treating metabolic disorders
WO2018009256A1 (en) 2016-03-29 2018-01-11 Respirerx Pharmaceuticals, Inc. Compositions and methods for treating attention deficit disorders
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same
WO2019177937A1 (en) 2018-03-12 2019-09-19 Arbutus Biopharma, Inc. Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
KR20200142529A (ko) 2018-04-12 2020-12-22 아뷰터스 바이오파마 코포레이션 치환된 피리디논-함유 트리사이클릭 화합물의 제조 방법
AU2019382521B2 (en) 2018-11-22 2023-11-16 Fujian Akeylink Biotechnology Co., Ltd. Crystal form of hepatitis B surface antigen inhibitor
EP4121072A1 (en) * 2020-03-20 2023-01-25 Amathus Therapeutics, Inc. Cyclic sulfonamide derivatives as trap1 modulators and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1238719A (es) 1968-11-01 1971-07-07
CA2138533C (en) 1992-07-24 2009-04-14 Gary S. Lynch Drugs that enhance synaptic responses mediated by ampa receptors
CN1168140A (zh) 1995-01-06 1997-12-17 弗·哈夫曼-拉罗切有限公司 羟甲基咪唑并二氮杂䓬及其酯
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
DE69831446T2 (de) 1997-06-09 2006-06-14 Pfizer Prod Inc Chinazolin-4-on AMPA Antagonisten
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
CA2320354A1 (en) * 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
US6124278A (en) 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
AR036092A1 (es) 2004-08-11
HRP20031007A2 (en) 2005-10-31
EP1399450B1 (en) 2008-03-19
SK287150B6 (sk) 2010-01-07
JP4435561B2 (ja) 2010-03-17
CZ20033376A3 (en) 2004-04-14
CZ300052B6 (cs) 2009-01-21
CA2450274C (en) 2010-12-21
CA2450274A1 (en) 2002-12-19
ATE389659T1 (de) 2008-04-15
TWI232863B (en) 2005-05-21
SK15182003A3 (sk) 2004-05-04
CO5550447A2 (es) 2005-08-31
PL366721A1 (en) 2005-02-07
CN1257908C (zh) 2006-05-31
BR0210222A (pt) 2004-04-13
US7504390B2 (en) 2009-03-17
RU2004100310A (ru) 2005-06-10
US7307073B2 (en) 2007-12-11
EP1399450A1 (en) 2004-03-24
IL158905A (en) 2008-12-29
AU2002314144B2 (en) 2008-01-31
HUP0400154A2 (hu) 2004-07-28
JP2004533466A (ja) 2004-11-04
WO2002100865A1 (en) 2002-12-19
US20040171605A1 (en) 2004-09-02
KR100863255B1 (ko) 2008-10-15
NO328705B1 (no) 2010-05-03
NZ529670A (en) 2006-02-24
PE20030097A1 (es) 2003-02-08
ZA200309382B (en) 2005-03-02
NO20035486D0 (no) 2003-12-10
HK1061858A1 (en) 2004-10-08
DE60225689T2 (de) 2008-07-17
CN1514835A (zh) 2004-07-21
DE60225689D1 (de) 2008-04-30
KR20040006030A (ko) 2004-01-16
MXPA03011563A (es) 2004-03-18
ES2301651T3 (es) 2008-07-01
IS2526B (is) 2009-07-15
RU2279434C2 (ru) 2006-07-10
HUP0400154A3 (en) 2007-05-02
IL158905A0 (en) 2004-05-12
US20080139529A1 (en) 2008-06-12
IS7036A (is) 2003-11-13

Similar Documents

Publication Publication Date Title
CY1109558T1 (el) Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων
ECSP045368A (es) "antagonistas de los receptores de trombina"
AR022303A1 (es) Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
AR037647A1 (es) Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
ES2184772T3 (es) Derivados de bifenilo, procedimiento para su preparacion y su utilizacion como medicamentos.
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
PE20020470A1 (es) Derivados de pirazol como inhibidores de las enzimas proteina quinasas
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
UY28150A1 (es) Agentes terapeuticos
AR042668A1 (es) Derivados de fosfonoxi quinazolinas y su uso farmaceutico
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
PA8456901A1 (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
ECSP034891A (es) Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa
PE20050141A1 (es) DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA
PE54294A1 (es) Derivado de 5-aminoalquil-1,4-benzodiazepina
AR029214A1 (es) Compuestos inhibidores de fosfodiesterasa - 4: 8 - arilquinolinas sustituidas, composiciones farmaceuticas, metodo de tratamiento que las utiliza